# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Cook (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX006-SYN
- Date: 2026-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okafor-Brandt, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Sixteen-week review of blood pressure, potassium and kidney function four weeks after starting losartan; mood and stroke prevention. **S**

## History of present illness

Mr. Cook returns four weeks after changing from hydrochlorothiazide to losartan 50 mg, with amlodipine 5 mg, atorvastatin 40 mg and aspirin 81 mg. He has no dizziness, cough or swelling, and no gout. His home readings average 124/76. He did not have the blood test that was meant to be done one to two weeks after starting losartan; it was drawn this morning. His prison medical records have arrived and record no earlier diagnoses or vaccinations. His fecal immunochemical test was negative. He feels more settled, is writing every morning, and still feels a sting of shame when he is recognized, though it troubles him less. He has had no stroke symptoms. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 124/76 |
| Medicine effects | No dizziness, cough or swelling; no gout |
| Records | Prison records received; no earlier diagnoses or vaccinations recorded |
| Screening | Fecal immunochemical test negative |
| Mood | More settled; PHQ-9 4 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Respiratory | Negative | No cough |
| Neurological | Negative | No weakness, numbness, speech trouble, loss of vision, or dizziness |
| Musculoskeletal | Negative | No joint pain or muscle aches |
| Psychiatric | Negative | Mood better; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Losartan 50 mg tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 74.8 kg; BMI 24.4 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.06 mg/dL; eGFR: 78 mL/min/1.73 m²; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.06 mg/dL at this visit **S**
- eGFR: 86 mL/min/1.73 m² at baseline, 78 mL/min/1.73 m² at this visit **S**
- PHQ-9: 7 at baseline, 4 at this visit **S**

## Immunizations given today

- Influenza vaccine, high-dose, trivalent **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 66, weight 74.8 kg |
| Neck | Soft right carotid bruit, unchanged |
| Cardiovascular | Regular rhythm; no ankle edema |
| Psychiatric | Brighter; engaged and humorous |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension, at target** (I10). Office 126/76 and home average 124/76 on losartan 50 mg and amlodipine 5 mg, below 130/80. Potassium 4.5 mmol/L, sodium 139 mmol/L, creatinine 1.06 mg/dL and eGFR 78, a small expected change from 1.04 on starting losartan. **S**
   - Continue losartan 50 mg and amlodipine 5 mg.
   - Electrolytes and creatinine every six months.
   - Home readings once a week.
2. **Asymptomatic right internal carotid stenosis** (I65.21). No symptoms; blood pressure and LDL at target on best medical therapy. **S**
   - Continue atorvastatin 40 mg and aspirin 81 mg.
   - Repeat duplex in about nine months; vascular neurology review if stenosis reaches 70 percent or symptoms occur.
   - Call 911 at once for any BE FAST sign.
3. **Re-entry after incarceration** (Z65.2). Housing, income and coverage settled; PHQ-9 4, down from 7, with no thoughts of self-harm; records received. **S**
   - Influenza and second zoster vaccine doses today; COVID-19 vaccine offered again and declined.
   - Annual wellness visit next summer.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure, seated, average of two readings | Every visit | Completed today | 126/76 mmHg; at target |
| Self-management | Home blood pressure monitoring | At diagnosis and after each treatment change | Completed today | Average 124/76 |
| Laboratory | Sodium, potassium, creatinine and eGFR | Baseline; early after starting a diuretic or an ARB; then every 6 months | Completed today | Sodium 139, potassium 4.5 mmol/L, creatinine 1.06 mg/dL, eGFR 78. Protocol deviation: the potassium and creatinine check ordered for one to two weeks after starting losartan was not drawn, because no date was booked and no visit fell in that window; it was drawn today, four weeks after starting. No harm resulted: potassium is normal and creatinine rose only 0.02 mg/dL. Corrective action: book the blood test with a date when a renin-angiotensin drug or a diuretic is started |
| Laboratory | Lipid panel | Baseline; 4 to 12 weeks after starting a statin; then every 3 to 12 months | Up to date | LDL 68 mg/dL four weeks ago; next in 6 to 12 months |
| Laboratory | Urine albumin-to-creatinine ratio | Annually | Up to date | 18 mg/g at intake; next due at the annual visit |
| Laboratory | HbA1c or fasting glucose | Annually | Up to date | HbA1c 5.5% at intake |
| Medication safety | ARB effects: dizziness, potassium, creatinine | Early after starting, then every visit | Completed today | No dizziness; potassium and creatinine normal |
| Medication safety | Antiplatelet adherence and bleeding | Every visit | Completed today | No bleeding |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | No muscle symptoms |
| Imaging | Carotid duplex ultrasound for known 50 percent or greater stenosis on medical therapy | At diagnosis, then yearly | Up to date | Next duplex due in about nine months |
| Examination | Peripheral pulses and ankle-brachial index | Every 2 to 3 years at 65 or older | Due | Ankle-brachial index at the annual wellness visit |
| Self-management | Stroke warning signs (BE FAST) and calling 911 | Every visit | Completed today | No symptoms; knows the signs |
| Survey | Depression screen (PHQ-9) | Annually | Completed today | PHQ-9 4, from 7 at intake |
| Self-management | Re-entry social needs: housing, income, benefits, records | Every visit until settled | Completed today | Settled; records received |

## Goal progress

- Office and home blood pressure below 130/80 mmHg by four months. Outcome by 2026-10-27: Office 126/76 on amlodipine and losartan. **S**
- LDL cholesterol lowered by at least half on a statin. Outcome by 2026-09-29: LDL 68 mg/dL, from 148 mg/dL, on atorvastatin 40 mg. **S**
- Knows the warning signs of stroke and to call 911 at once. Outcome by 2026-07-21: Taught and repeated back the BE FAST signs at the consultation visit. **S**
- A stable room, Social Security and Medicare in place, and a health insurance card in hand. Outcome by 2026-09-29: Six-month lease on his room; retirement benefits and Medicare approved. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025), American Heart Association; American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and stroke/TIA monographs (2026), Aether Forge
- 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association (Bushnell C, et al. Stroke 2024;55:e344-e424) (2024), American Heart Association/American Stroke Association
- Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease (AbuRahma AF, et al. J Vasc Surg 2022;75(1S):4S-22S) (2021), Society for Vascular Surgery
- 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2019;139:e1082-e1143) (2018), American Heart Association; American College of Cardiology
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in three months, with home readings. Annual wellness visit next summer. Repeat carotid duplex in about nine months. **S**

